drugset

drugset / Trial / NCT02241928

Stem Cell Therapy in Muscular Dystrophy

NCT02241928 ↗

Phase 1 Withdrawn Neurogen Brain and Spine Institute

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.

Timeline

Start: 2009-01
Primary completion: 2018-12
Completion: 2019-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Stem Cell	Cell therapy	—	Intrathecal

Indications